Badanie kliniczne III fazy oceniające zastosowanie pazopanibu w leczeniu raka nerki – komentarz do badania

Journal Title: OncoReview - Year 2012, Vol 2, Issue 1

Abstract

Authors and Affiliations

Kazimierz Drosik

Keywords

Related Articles

Rola kinaz JAK w patogenezie nowotworów mieloproliferacyjnych Philadelphia-ujemnych. Możliwości terapii celowanej

W ostatnich latach dokonał się istotny postęp w zrozumieniu patogenezy nowotworów mieloproliferacyjnych, w szczególności tych z mutacjami w obrębie genu JAK2. W 2005 roku liczne grupy badawcze potwierdziły występowanie m...

Radiotherapy in patients with cardiac implantable electronic devices – clinical experience

The number of patients with cardiac implantable electronic devices (CIEDs) constantly increases and due to growing incidence of cancer, many of them will require an anticancer treatment. At least a half of patients treat...

Lymphoma-induced hemophagocytic lymphohistiocytosis (HLH)– case report

Hemophagocytic lymphohistiocytosis (HLH) is a rare (especially in adults) syndrome in which hyperinflammation leads to fever, hepatosplenomegaly, pancytopenia and when untreated leads to death. Characteristic laboratory...

Treatment of multiple superficial basal cell carcinomas with topical imiquimod

Basal cell carcinoma is the most common malignancy of man. The use of the topical imiquimod 5% cream offers a noninvasive, nonsurgical, and an effective option for the treatment of primary types superficial basal cell ca...

The New Classification of NET

There are three imporant directions in the field of GEP NET. The first one is the NET Registry which collects the data from different clinical centers, that can be compared, providing the konwledge of these tumors. The s...

Download PDF file
  • EP ID EP53145
  • DOI -
  • Views 223
  • Downloads 0

How To Cite

Kazimierz Drosik (2012). Badanie kliniczne III fazy oceniające zastosowanie pazopanibu w leczeniu raka nerki – komentarz do badania. OncoReview, 2(1), -. https://europub.co.uk/articles/-A-53145